Risk and safety profile in checkpoint inhibitors on non-small-cel lung cancer: A systematic review

Treating non-small-cell lung cancer (NSCLC) has gained increased importance in recent years due to the high mortality rate and dismal five-year survival rate. Immune checkpoint inhibitors (ICI) are a promising approach with exceptional outcomes in NSCLC thanks to the antigenic nature of cells. Conve...

Full description

Saved in:
Bibliographic Details
Published in:Human vaccines & immunotherapeutics 2024-12, Vol.20 (1), p.2365771
Main Author: Majernikova, Sara Maria
Format: Article
Language:English
Subjects:
Carcinoma, Non-Small-Cell Lung - drug therapy
Humans
Immune Checkpoint Inhibitors - adverse effects
Immune Checkpoint Inhibitors - therapeutic use
Immunotherapy - adverse effects
Immunotherapy - methods
Lung Neoplasms - drug therapy
Nanoparticles
Treatment Outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Treating non-small-cell lung cancer (NSCLC) has gained increased importance in recent years due to the high mortality rate and dismal five-year survival rate. Immune checkpoint inhibitors (ICI) are a promising approach with exceptional outcomes in NSCLC thanks to the antigenic nature of cells. Conversely, immune system over-stimulation with ICI is a double-edged sword that can lead to various negative effects ranging from mild to life-threatening. This review explores current breakthroughs in nanoparticle-based ICI and their limitations. The PubMed, Scopus and Web of Science were examined for relevant publications. Thirty-eight trials (  = 16,781) were included in the analyses. The mixed effects analyses on quantifying the treatment effect contributed significantly to the subgroups within studies for ICI treatment effect. Models confirmed ICI's higher impact on treatment effectivity and the decrease in respondents' mortality compared to conventional treatment regiments. ICI might be used as first-line therapy due to their proven effectiveness and safety profile.
ISSN:2164-554X
2164-554X
DOI:10.1080/21645515.2024.2365771